Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus + Bevacizumab in Stage III/IV Melanoma
NCT00397982Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2008
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in melanoma, sponsored by National Cancer Institute. Primary endpoint: Objective Tumor Response Rate up to 18 weeks. Started Jan 2008; status: completed.
02
Drugs
temsirolimus
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00397982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00397982.